KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Swaminathan Iyer, Neha Mehta-Shah, Ranjana Advani, Nancy L Bartlett, Jacob H Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Onder Alpdogan, Tatyana A Feldman, Vincent Camus, Giuseppe Gritti, Pier Luigi Zinzani, David Belada, Jiri Mayer, Ilseung Choi, June-Won Cheong, Evelyn Rustia, Keenan Fenton, Michelle Fanale, Kerry J Savage, Steven M Horwitz

Blood Adv 9(23) 5976-5987

PMID40829107
PMCIDPMC12686796
DOI10.1182/bloodadvances.2024015282
发表日期2025-08-19
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluorodeoxyglucose PET scans after cycle 4 (PET4) and end-of-treatment-based response, and correlated with PFS per investigator and OS. PET4 response was determined by Deauville score (scores of 1-3 were considered negative [PET4-negative] and 4-5 positive [PET4-positive]) by independent review. Overall, 452 patients were randomized 1:1 to the BV-CHP (n = 226) and CHOP (n = 226) arms. Of these, 32 in the BV-CHP arm and 41 in the CHOP arm were not evaluable for PET4. In both arms, PET4-negative status was associated with improved PFS (BV-CHP: HR, 0.36; 95% CI, 0.19-0.66; CHOP: HR, 0.26; 95% CI, 0.17-0.41) and OS (BV-CHP: HR, 0.38; 95% CI, 0.18-0.78; CHOP: HR, 0.24; 95% CI, 0.14-0.41) compared with PET4-positive status. Among patients with systemic anaplastic large cell lymphoma, PET4-negative patients had improved PFS (BV-CHP: HR, 0.28; 95% CI, 0.14-0.60; CHOP: HR, 0.31; 95% CI, 0.17-0.56) and OS (BV-CHP: HR, 0.38; 95% CI, 0.16-0.94; CHOP: HR, 0.25; 95% CI, 0.12-0.55) compared with PET4-positive patients. In this exploratory analysis, PET4-negative status by Deauville score was associated with improved long-term PFS and OS in both the BV-CHP and CHOP arms. This trial was registered at www.ClinicalTrials.gov as #NCT01777152.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

BV-CHP_PFS_

PFS

Figure 1 · Panel BV-CHP_PFS_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel BV-CHP_PFS_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal
查看结果
BV-CHP_OS_

OS

Figure 1 · Panel BV-CHP_OS_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel BV-CHP_OS_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 3.

Kaplan-Meier estimate of PFS and OS by cycle 4 PET status in the total population. PFS in the BV-CHP (A) and CHOP (B) arms, and OS in the BV-CHP (C) and CHOP (D) arms.

A

PFS

Figure 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 3. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Study design of the ECHELON-2 trial. ∗Targeting 75% (±5%) ALCL per European Union and Canadian regulatory commitment. AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; EATL, enteropathy-associated T-cell lymphoma; HSTCL, hepatosplenic T-cell lymphoma; IPI, International Prognostic Index; PTCL-NOS, PTCL, not otherwise specified; q3w, every 3 weeks; R, randomized.
非 KM Figure
Figure 2.Cycle 4 PET status and EOT response in the total population and sALCL subgroup. NA, not available; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
非 KM Figure
Figure 4.Kaplan-Meier estimate of PFS and OS by cycle 4 PET status in the sALCL subgroup. PFS in the BV-CHP (A) and CHOP (B) arms, and OS in the BV-CHP (C) and CHOP (D) arms.
非 KM Figure